Novel expression of Neuropilin 1 on human tumor-infiltrating lymphocytes in colorectal cancer liver metastases

Expert Opinion on Therapeutic Targets

Volumn 19, Issue 2, 2015, Pages 147-161

  Chaudhary, Belal ^a,b   Elkord, Eyad ^a,b,c  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b UNIVERSITY OF SALFORD   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Colorectal cancer liver metastases; Expression; Neuropilin 1; Regulatory T cells; Tumor infiltrating lymphocytes

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; NEUROPILIN 1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR HELIOS; TUMOR MARKER; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CANCER TISSUE; COCULTURE; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; LIVER METASTASIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; PROTEIN EXPRESSION ASSAY; PROTEIN INDUCTION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE; UPREGULATION; CASE CONTROL STUDY; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; MONONUCLEAR CELL; PATHOLOGY; PROGNOSIS; SECONDARY;

CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKOCYTES, MONONUCLEAR; LIVER NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; NEUROPILIN-1; PROGNOSIS; T-LYMPHOCYTE SUBSETS; UP-REGULATION;

EID: 84921282496     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.977784     Document Type: Article

References (56)

1. Kim KJ, Lee KS, Cho HJ, et al. Prognostic implications of tumor-infiltrating FoxP3+ regulatory T cells and CD8+ cytotoxic T cells in microsatelliteunstable gastric cancers. Hum Pathol 2014;45(2):285-93
2. Chaudhary B, Abd Al Samid M, Al-Ramadi BK, Elkord E. Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer. Expert Opin Biol Ther 2014;14(7):931-45
3. Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008;8(4):299-308
4. Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009;114(8):1537-44
5. Whiteside TL, Schuler P, Schilling B. Induced and natural regulatory T cells in human cancer. Expert Opin Biol Ther 2012;12(10):1383-97
6. Whiteside TL. Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression? Cancer Immunol Immunother 2014;63(1):67-72
7. Marabelle A, Kohrt H, Sagiv-Barfi I, et al. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest 2013;123(6):2447-63
8. Sugiyama D, Nishikawa H, Maeda Y, et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci USA 2013;110(44):17945-50
9. Chaudhary B, Khaled YS, Ammori BJ, Elkord E. Neuropilin 1: function and therapeutic potential in cancer. Cancer Immunol Immunother 2014;63(2):81-99
10. Battaglia A, Buzzonetti A, Martinelli E, et al. Selective changes in the immune profile of tumor-draining lymph nodes after different neoadjuvant chemoradiation regimens for locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 2010;76(5):1546-53
11. Battaglia A, Buzzonetti A, Monego G, et al. Neuropilin-1 expression identifies a subset of regulatory T cells in human lymph nodes that is modulated by preoperative chemoradiation therapy in cervical cancer. Immunology 2008;123(1):129-38
12. Renand A, Milpied P, Rossignol J, et al. Neuropilin-1 expression characterizes T follicular helper (Tfh) cells activated during B cell differentiation in human secondary lymphoid organs. PLoS One 2013;8(12):e85589
13. Nirschl CJ, Ceccato CM, Alme A, et al. Expression of neuropilin-1 on in vivo induced regulatory T cells. J Immunother Cancer 2013;1(Supp 1):167
14. Weiss JM, Bilate AM, Gobert M, et al. Neuropilin 1 is expressed on thymus-derived natural regulatory T cells, but not mucosa-generated induced Foxp3+ T reg cells. J Exp Med 2012;209(10):1723-42. S1
15. Yadav M, Louvet C, Davini D, et al. Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med 2012;209(10):1713-22. S1-19
16. E XQ, Meng HX, Cao Y, et al. Distribution of regulatory T cells and interaction with dendritic cells in the synovium of rheumatoid arthritis. Scand J Rheumatol 2012;41(6):413-20
17. Yadav M, Stephan S, Bluestone JA. Peripherally induced tregs - role in immune homeostasis and autoimmunity. Front Immunol 2013;4:232
18. Miao HQ, Lee P, Lin H, et al. Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. FASEB J 2000;14(15):2532-9
19. Haixia D, Jingsong Z, Lei J, et al. Gene expression of neuropilin-1 and its receptors, VEGF/Semaphorin 3a, in normal and cancer cells. Cell Biochem Biophys 2011;59(1):39-47
20. Jubb AM, Strickland LA, Liu SD, et al. Neuropilin-1 expression in cancer and development. J Pathol 2012;226(1):50-60
21. Kumar A, Huo S, Zhang X, et al. Neuropilin-1-targeted gold nanoparticles enhance therapeutic efficacy of platinum (iv) drug for prostate cancer treatment. ACS Nano 2014;8(5):4205-20
22. Borriello L, Montes M, Lepelletier Y, et al. Structure-based discovery of a small non-peptidic Neuropilins antagonist exerting in vitro and in vivo anti-tumor activity on breast cancer model. Cancer Lett 2014;349(2):120-7
23. Xin Y, Li J, Wu J, et al. Pharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel antiangiogenesis agent, in two phase I trials in patients with advanced solid tumors. Clin Cancer Res 2012;18(21):6040-8
24. Shin TH, Sung ES, Kim YJ, et al. Enhancement of the tumor penetration of monoclonal antibody by fusion of a neuropilin-targeting peptide improves the antitumor efficacy. Mol Cancer Ther 2014;13(3):651-61
25. Liang WC, Dennis MS, Stawicki S, et al. Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library. J Mol Biol 2007;366(3):815-29
26. Sugimoto N, Oida T, Hirota K, et al. Foxp3-dependent and -independent molecules specific for CD25+CD4+ natural regulatory T cells revealed by DNA microarray analysis. Int Immunol 2006;18(8):1197-209
27. Elkord E, Sharma S, Burt DJ, Hawkins RE. Expanded subpopulation of FoxP3+ T regulatory cells in renal cell carcinoma co-express Helios, indicating they could be derived from natural but not induced Tregs. Clin Immunol 2011;140(3):218-22
28. Wainwright DA, Sengupta S, Han Y, Lesniak MS. Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors. Neuro Oncol 2011;13(12):1308-23
29. Zabransky DJ, Nirschl CJ, Durham NM, et al. Phenotypic and functional properties of Helios+ regulatory T cells. PLoS One 2012;7(3):e34547
30. Itzhaki O, Hovav E, Ziporen Y, et al. Establishment and large-scale expansion of minimally cultured young tumor infiltrating lymphocytes for adoptive transfer therapy. J Immunother 2011;34(2):212-20
31. Elkord E. Frequency of human T regulatory cells in peripheral blood is significantly reduced by cryopreservation. J Immunol Methods 2009;347(1-2):87-90
32. Elkord E, Al-Ramadi BK. Helios expression in FoxP3(+) T regulatory cells. Expert Opin Biol Ther 2012;12(11):1423-5
33. Elkord E. Comment on "Expression of Helios in peripherally induced Foxp3+ regulatory T cells". J Immunol 2012;189(2):500; author reply 00-1
34. Scurr M, Ladell K, Besneux M, et al. Highly prevalent colorectal cancer-infiltrating LAP(+) Foxp3(-) T cells exhibit more potent immunosuppressive activity than Foxp3(+) regulatory T cells. Mucosal Immunol 2014;7(2):428-39
35. Milpied P, Renand A, Bruneau J, et al. Neuropilin-1 is not a marker of human Foxp3+ Treg. Eur J Immunol 2009;39(6):1466-71
36. Lim AY, Price P, Beilharz MW, French MA. Cell surface markers of regulatory T cells are not associated with increased forkhead box p3 expression in blood CD4+ T cells from HIV-infected patients responding to antiretroviral therapy. Immunol Cell Biol 2006;84(6):530-6
37. Battaglia A, Buzzonetti A, Baranello C, et al. Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer. Cancer Immunol Immunother 2009;58(9):1363-73
38. Catalano A. The neuroimmune semaphorin-3A reduces inflammation and progression of experimental autoimmune arthritis. J Immunol 2010;185(10):6373-83
39. Dzionek A, Inagaki Y, Okawa K, et al. Plasmacytoid dendritic cells: from specific surface markers to specific cellular functions. Hum Immunol 2002;63(12):1133-48
40. Raffin C, Pignon P, Celse C, et al. Human memory Helios- FOXP3+ regulatory T cells (Tregs) encompass induced Tregs that express Aiolos and respond to IL-1beta by downregulating their suppressor functions. J Immunol 2013;191(9):4619-27
41. Baine I, Basu S, Ames R, et al. Helios induces epigenetic silencing of IL2 gene expression in regulatory T cells. J Immunol 2013;190(3):1008-16
42. Akimova T, Beier UH, Wang L, et al. Helios expression is a marker of T cell activation and proliferation. PLoS One 2011;6(8):e24226
43. Bourbie-Vaudaine S, Blanchard N, Hivroz C, Romeo PH. Dendritic cells can turn CD4+ T lymphocytes into vascular endothelial growth factorcarrying cells by intercellular neuropilin-1 transfer. J Immunol 2006;177(3):1460-9
44. Sarris M, Andersen KG, Randow F, et al. Neuropilin-1 expression on regulatory T cells enhances their interactions with dendritic cells during antigen recognition. Immunity 2008;28(3):402-13
45. Tordjman R, Lepelletier Y, Lemarchandel V, et al. A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response. Nat Immunol 2002;3(5):477-82
46. Gai XD, Song Y, Li C, et al. Potential role of plasmacytoid dendritic cells for FOXP3+ regulatory T cell development in human colorectal cancer and tumor draining lymph node. Pathol Res Pract 2013;209(12):774-8
47. Feyler S, Scott GB, Parrish C, et al. Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent. PLoS One 2012;7(5):e35981
48. Glinka Y, Stoilova S, Mohammed N, Prud'homme GJ. Neuropilin-1 exerts co-receptor function for TGF-beta-1 on the membrane of cancer cells and enhances responses to both latent and active TGF-beta. Carcinogenesis 2011;32(4):613-21
49. Delgoffe GM, Woo SR, Turnis ME, et al. Stability and function of regulatory T cells is maintained by a neuropilin-1- semaphorin-4a axis. Nature 2013;501(7466):252-6
50. Hansen W. Neuropilin 1 guides regulatory T cells into VEGF-producing melanoma. Oncoimmunology 2013;2(2):e23039
51. Hansen W, Hutzler M, Abel S, et al. Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth. J Exp Med 2012;209(11):2001-16
52. Jia H, Cheng L, Tickner M, et al. Neuropilin-1 antagonism in human carcinoma cells inhibits migration and enhances chemosensitivity. Br J Cancer 2010;102(3):541-52
53. Casazza A, Laoui D, Wenes M, et al. Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell 2013;24(6):695-709
54. Staton CA, Koay I, Wu JM, et al. Neuropilin-1 and neuropilin-2 expression in the adenoma-carcinoma sequence of colorectal cancer. Histopathology 2013;62(6):908-15
55. Paoli EE, Ingham ES, Zhang H, et al. Accumulation, internalization and therapeutic efficacy of neuropilin-1-targeted liposomes. J Control Release 2014;178:108-17
56. Piechnik A, Dmoszynska A, Omiotek M, et al. The VEGF receptor, neuropilin-1, represents a promising novel target for chronic lymphocytic leukemia patients. Int J Cancer 2013;133(6):1489-96